The purpose of this study is to evaluate the efficacy and safety of apatinib plus EGFR-TKI as first line treatment in patients with non-squamous NSCLC harboring EGFR mutation.
Name: Apatinib
Description: apatinib 500mg qd po plus Erlotinib 150mg qd po / apatinib 500mg qd po plus Icotinib 125mg tid poType: Drugapatinib
Description: Baseline to measured date of progression or death from any cause
Measure: Progression free survival Time: evaluated in two years since the treatment beganDescription: Baseline to measured stable disease
Measure: Objective response rate Time: tumor assessment every 8 weeks,up to two yearsDescription: Baseline to measured progressive disease
Measure: Disease control rate (DCR) Time: tumor assessment every 8 weeks,up to two yearsDescription: Baseline to measured date of death from any cause
Measure: Overall survival (OS) Time: the first day of treatment to death or last survival confirm date,up to two yearsDescription: throughout study
Measure: Adverse events Time: evaluated in the two years since the treatment began according to the Common Terminology Criteria for Adverse Events Version 4.0Single Group Assignment
There is one SNP
Inclusion Criteria: 1. Age:18 to 75 years old (man or female); 2. Pathologically diagnosed with non-squamous NSCLC; 3. Imageology diagnosed with locally advanced/metastatic or recurrent (stage ⅢB - IV); 4. Histologically or cytologic confirmed,harboring an activating EGFR mutation (19del or 21 L858R); 5. None previous chemotherapy or targeted therapy.(NOTE: --- L858R ---